Por: The Advocate Health November 07, 2022
Will the new experimental drug lecanemab for Alzheimer’s be available soon?In July, the U.S. Food and Drug Administration accepted an application for accelerated approval for lecanemab, and just recently, sponsors of the drug, Biogen and Eisai, announced positive results from an ongoing Phase 3 clinical trial. Lecanemab slowed the rate of cognitive decline by 27%, reducing beta amyloid plaques in the brain and decelerating the patients’... + full article
Slate USA Tech October 30, 2022
For decades, there had been no real medical game changers in Alzheimer’s research—until last year. The FDA approved a controversial drug, one with only mixed clinical results. At this point, even the manufacturer of this drug, called Aduhelm, has all but abandoned it. There... + más
Reimagining Alzheimer’s (Part 4): Cautious Optimism For A New Alzheimer’s Disease Treatment | Forbes
How To Spot The Early Signs Of Alzheimer's | Newsweek
Forbes USA Tech October 22, 2022
A person walks on a suspended rope bridge in the clouds. Extreme attraction.getty This article is the fourth installment in my series on Alzheimer’s disease. Read more about Alzheimer’s disease in , , and of the series. The pharmaceutical and biotech companies, Eisai and... + más
COVID-19 in seniors linked to increased Alzheimer’s risk, study finds | Portland Press Herald
Variety of factors play a role in the development of Alzheimer's | The Advocate
ABC News USA Health September 30, 2022
WASHINGTON -- A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.Amylyx Pharmaceuticals said the Food and... + más
Highly debated Amylyx Pharmaceuticals ALS drug wins FDA approval | New York Post
ALS drug wins FDA approval despite questionable data | WPLG Local 10
CNN USA Health September 28, 2022
CNN — A monoclonal antibody treatment for Alzheimer’s disease called lecanemab slows the progression of cognitive decline by 27% compared with a placebo, drugmakers Biogen and Eisai said Tuesday. The drug, tested in a Phase 3 global clinical trial, also met all secondary... + más
New test can detect plaques early in the disease: Alzheimer's Q&A | The Advocate
Experimental Alzheimer’s drug slows cognitive decline in trial, firms say | Portland Press Herald
Newsweek USA Health September 24, 2022
The Alzheimer's Association defines Alzheimer's as a brain disease that causes a slow decline in memory, thinking and reasoning skills. Dementia refers to the symptoms of Alzheimer's that can worsen over time.They predict that by 2050, the number of people aged 65... + más
There's a growing dementia crisis in the veteran community: Alzheimer's Q&A | The Advocate
Portland Press Herald USA Health September 24, 2022
A study using the electronic health records of more than 6 million Americans over age 65 found that those who had COVID-19 ran a greater risk of receiving a new diagnosis of Alzheimer’s disease within a year. The study, led by researchers at Case Western Reserve University... + más
The Advocate USA Health September 17, 2022
Are U.S. veterans more at risk for Alzheimer’s or other dementias?The U.S. is in the midst of a dramatic rise in the number of veterans with Alzheimer’s disease and other dementias, and many of these new cases are directly attributable to military service.According to a 2017... + más
Stroke can lead to vascular dementia: Alzheimer's Q&A | The Advocate
Alzheimer's Q&A: Let go of negative thoughts | The Advocate
About iurex | Privacy Policy | Disclaimer |